<DOC>
	<DOCNO>NCT00675493</DOCNO>
	<brief_summary>This trial conduct Europe . The aim observational study evaluate blood glucose control ( HbA1c ) use NovoMix® 30 treatment type 1 type 2 diabetes normal clinical practice condition Romania .</brief_summary>
	<brief_title>Observational Study Type 1 Type 2 Diabetes Patients Having Switched From Human Premixes NovoMix®30</brief_title>
	<detailed_description />
	<mesh_term>Diabetes Mellitus</mesh_term>
	<mesh_term>Diabetes Mellitus , Type 2</mesh_term>
	<mesh_term>Diabetes Mellitus , Type 1</mesh_term>
	<mesh_term>Insulin aspart , insulin aspart protamine drug combination 30:70</mesh_term>
	<mesh_term>Insulin</mesh_term>
	<mesh_term>Biphasic Insulins</mesh_term>
	<mesh_term>Insulin Aspart</mesh_term>
	<mesh_term>Insulin , Isophane</mesh_term>
	<criteria>Type 1 type 2 diabetic treat human premix insulin ( selection subject discretion individual physician ) . Subjects currently treat biphasic insulin aspart 30 Subjects previously enrol study Subjects hypersensitivity biphasic insulin aspart 30 excipients Women pregnant intention become pregnant within next 6 month Children 10 year age</criteria>
	<gender>All</gender>
	<minimum_age>10 Years</minimum_age>
	<maximum_age>75 Years</maximum_age>
	<verification_date>February 2016</verification_date>
</DOC>